vTv Therapeutics (NASDAQ:VTVT) Now Covered by HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report issued on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $36.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 99.00% from the stock’s previous close. HC Wainwright also issued estimates for vTv Therapeutics’ Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.

Separately, StockNews.com began coverage on vTv Therapeutics in a research note on Thursday, March 27th. They set a “sell” rating for the company.

vTv Therapeutics Stock Performance

Shares of VTVT stock opened at $18.09 on Wednesday. The stock’s 50 day simple moving average is $17.88 and its 200 day simple moving average is $15.72. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $29.19. The company has a market capitalization of $57.71 million, a price-to-earnings ratio of -3.99 and a beta of 0.81.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

Institutional Trading of vTv Therapeutics

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics during the fourth quarter valued at about $25,000. Geode Capital Management LLC increased its stake in vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the period. Finally, FMR LLC acquired a new position in vTv Therapeutics in the 3rd quarter valued at approximately $2,402,000. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.